- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Small cell lung cancer (SCLC)
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1376KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 347KB)
Durvalumab – November 2020
Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi®
Last updated
5 March 2021